{
    "ticker": "LTM",
    "name": "Lantheus Holdings, Inc.",
    "description": "Lantheus Holdings, Inc. is a leading provider of innovative diagnostic imaging agents and solutions focused on diagnosing and treating cancer and other serious conditions. Founded in 1956, Lantheus has grown into a prominent player in the biopharmaceutical industry, focusing on developing products that enhance patient care. The company specializes in nuclear imaging and has a portfolio that includes targeted imaging agents such as Pylarify (piflufolastat F-18), used in the detection of prostate cancer. Lantheus is committed to advancing the field of molecular imaging and improving clinical outcomes through its state-of-the-art technologies. With a robust pipeline of investigational products, Lantheus aims to address unmet medical needs in oncology and cardiology. The company operates with a strong emphasis on research and development, continuously seeking to innovate and expand its product offerings to enhance diagnostic accuracy and treatment efficacy. In addition to its focus on imaging agents, Lantheus is dedicated to educational initiatives to support healthcare professionals and improve patient access to vital diagnostic services. The company's mission is to provide healthcare solutions that improve the lives of patients and contribute to the advancement of healthcare globally.",
    "industry": [
        "Healthcare",
        "Biotechnology"
    ],
    "headquarters": "North Billerica, Massachusetts, USA",
    "founded": "1956",
    "website": "https://www.lantheus.com",
    "ceo": "Mark C. C. S. M. D. A. T. C. S. M. D. A. T. C. S. M. D.",
    "social_media": {
        "twitter": "https://twitter.com/Lantheus",
        "linkedin": "https://www.linkedin.com/company/lantheus/"
    },
    "investor_relations": "https://investors.lantheus.com",
    "key_executives": [
        {
            "name": "Mark C. C. S. M. D. A. T. C. S. M. D.",
            "position": "CEO"
        },
        {
            "name": "Patricia A. M. M. D.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Imaging Agents",
            "products": [
                "Pylarify",
                "Definity"
            ]
        },
        {
            "category": "Diagnostic Solutions",
            "products": [
                "Cardiac Imaging Solutions"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lantheus Holdings, Inc. | Innovative Diagnostic Imaging Solutions",
        "meta_description": "Explore Lantheus Holdings, Inc., a leader in diagnostic imaging agents and solutions focused on cancer and serious conditions. Discover their innovative products, mission, and impact on healthcare.",
        "keywords": [
            "Lantheus",
            "Diagnostic Imaging",
            "Healthcare",
            "Biotechnology",
            "Cancer Diagnostics",
            "Pylarify"
        ]
    },
    "faq": [
        {
            "question": "What does Lantheus specialize in?",
            "answer": "Lantheus specializes in diagnostic imaging agents and solutions, particularly for oncology and serious conditions."
        },
        {
            "question": "Who is the CEO of Lantheus?",
            "answer": "Mark C. C. S. M. D. A. T. C. S. M. D. is the CEO of Lantheus Holdings, Inc."
        },
        {
            "question": "Where is Lantheus headquartered?",
            "answer": "Lantheus is headquartered in North Billerica, Massachusetts, USA."
        },
        {
            "question": "What are Lantheus's main products?",
            "answer": "Lantheus's main products include imaging agents like Pylarify and Definity."
        },
        {
            "question": "When was Lantheus founded?",
            "answer": "Lantheus was founded in 1956."
        }
    ],
    "competitors": [
        "MRK",
        "ABBV",
        "BMY",
        "REGN"
    ],
    "related_stocks": [
        "AAPL",
        "JNJ",
        "PFE",
        "AMGN"
    ]
}